Results 191 to 200 of about 262,268 (303)

Estrogens, Estrogen Receptors and Tumor Microenvironment in Ovarian Cancer. [PDF]

Int J Mol Sci, 2023
Kozieł MJ, Piastowska-Ciesielska AW.
europepmc   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries. [PDF]

NPJ Breast Cancer
Devakrishnan AK, Madasu C, Wang Y, Modukuri R, Bohren KM, MacKenzie KR, Young DW, Fuqua SAW, Matzuk MM, Palaniappan M.   +9 more
europepmc   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon, Chengsheng Ju, Kenneth K. C. Man, Rebecca Roylance, Diego Ottaviani, Chiara Creed, Michal Sladkowski, Alec Wisner, Li Wei, Pinkie Chambers   +9 more
wiley   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source

Reproducibility of Immunohistochemical Testing of Estrogen Receptors, Progesterone Receptors, Human Epidermal Growth Factor Receptor-2 (HER2) and Ki-67 in Vietnam. [PDF]

Br J Biomed Sci
Tu TA, Tin NV, Rhodes A, Anh DBQ, Dao LTH, Linh NTT, Nhu DTK, Nhung NTH, Cam LT, Hanh NTM, Cuong PN, Toan NT, Tuyen NK, Khanh DD, Ngan TTT, Thy LKM, Thanh NV, Tuan NQ, Nguyen VN, Nhu LTT, Bao NDC.   +20 more
europepmc   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, EarlyView.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Mineralocorticoid and estrogen receptors as sex-dependent modulators of vascular health in aging and obesity. [PDF]

J Pharmacol Exp Ther
Turner CG, de Oliveira K, Jaffe IZ, DuPont JJ.   +3 more
europepmc   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

Expression of Estrogen Receptors in Main Immune Organs in Sheep During Early Pregnancy. [PDF]

Int J Mol Sci
Yang Z, Zhang Y, Cao Z, Li Z, Zhang L, Yang L.   +5 more
europepmc   +1 more source